Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England.
Cleary M, Davison J, Gould R, Geberhiwot T, Hughes D, Mercer J, Morrison A, Murphy E, Santra S, Jarrett J, Mukherjee S, Stepien KM. Cleary M, et al. Among authors: gould r. Orphanet J Rare Dis. 2021 Jan 21;16(1):38. doi: 10.1186/s13023-021-01675-x. Orphanet J Rare Dis. 2021. PMID: 33478511 Free PMC article.
Cost-effectiveness of acceptance and commitment therapy for people living with motor neuron disease, and their health-related quality of life.
Keetharuth AD, Gould RL, McDermott CJ, Thompson BJ, Rawlinson C, Bradburn M, Bursnall M, Kumar P, Turton EJ, Tappenden P, White D, Howard RJ, Serfaty MA, McCracken LM, Graham CD, Al-Chalabi A, Goldstein LH, Lawrence V, Cooper C, Young T; COMMEND Collaboration Group. Keetharuth AD, et al. Among authors: gould rl. Eur J Neurol. 2024 Apr 25:e16317. doi: 10.1111/ene.16317. Online ahead of print. Eur J Neurol. 2024. PMID: 38660985
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Tawil R, Wagner KR, Hamel JI, Leung DG, Statland JM, Wang LH, Genge A, Sacconi S, Lochmüller H, Reyes-Leiva D, Diaz-Manera J, Alonso-Perez J, Muelas N, Vilchez JJ, Pestronk A, Gibson S, Goyal NA, Hayward LJ, Johnson N, LoRusso S, Freimer M, Shieh PB, Subramony SH, van Engelen B, Kools J, Leinhard OD, Widholm P, Morabito C, Moxham CM, Cadavid D, Mellion ML, Odueyungbo A, Tracewell WG, Accorsi A, Ronco L, Gould RJ, Shoskes J, Rojas LA, Jiang JG. Tawil R, et al. Among authors: gould rj. Lancet Neurol. 2024 May;23(5):477-486. doi: 10.1016/S1474-4422(24)00073-5. Lancet Neurol. 2024. PMID: 38631764 Clinical Trial.
Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial.
Howard R, Cort E, Rawlinson C, Wiegand M, Downey A, Lawrence V, Banerjee S, Bentham P, Fox C, Harwood R, Hunter R, Livingston G, Moniz-Cook E, Panca M, Raczek M, Ivenso C, Russell G, Thomas A, Wilkinson P, Freemantle N, Gould R. Howard R, et al. Among authors: gould r. Alzheimers Dement. 2024 Apr;20(4):2990-2999. doi: 10.1002/alz.13766. Epub 2024 Mar 13. Alzheimers Dement. 2024. PMID: 38477423 Free PMC article. Clinical Trial.
757 results